Meeting Register Page

M-Corps Showcase: Latham Biopharm Group - Developing Company Strategies to Enhance Non-Dilutive Funding Success

Non-dilutive funding is a great tool to help enhance a growing company’s developmental pipeline. Today’s presentation will dig into how LBG helps their clients navigate, secure, and manage non-dilutive funding. We will specifically dive into strategies to successfully align your company and product to be successfully. Ultimately, these strategies can vary significantly depending on the source of the non-dilutive funding and your company’s current overall business strategy. With our blend of experience across companies that have various sources of funding, LBG has helped answer many strategic questions to ensure that businesses are meeting their corporate goals. Here are a few examples:

• What agencies would be interested in my technology/product? What stage of development does my product need to be to look for non-dilutive funding.
• How can my company showcase the value of our technology/product to the USG?
• How can I marry our non-dilutive funding strategy with potential investors?

LBG’s expertise in both the life sciences arena and the government arena sets us apart from our competitors. We pride ourselves on our well-established contacts and our highly skilled team members, many of whom hold advanced degrees in the field of life sciences and utilize their expertise to meet your strategic goals.


Speakers:
Cassidy Cantin, Associate Director Non-Dilutive Funding
Chris Peterson, Associate Director Strategic Consulting

Jun 29, 2022 01:00 PM in Eastern Time (US and Canada)